Detail
| LncRNA Name | ANRIL |
| Synonyms | CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS |
| Region | GRCh38_9:21994778-22121097 Sequence |
| Ensembl | ENSG00000240498 |
| RefSeq | NR_003529 |
| Circulating | ✘ |
| Drug-resisitant | ✘ |
| Prognostic | ✔ |
| MiRNA | ✔ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | triple negative breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Luciferase reporter assay, RIP. |
| Sample | triple-negative breast cancer tissues, cell lines (MDA-MB-231, MDA-MB-468, MDA-MB-453,TB-549,MCF-7 and TD-47) |
| Expression Pattern | up-regulated |
| Function Description | Expression level of ANRIL was up-regulated in TNBC tumor tissue and cell lines compared to noncancerous tissue and non-TNBC cells.the up-regulated ANRIL expression was closely correlated to poor prognosis.ANRIL knockdown interfered by interference oligonucleotide could markedly suppress TNBC cells proliferation and enhance apoptosis. ANRIL overexpression modulated TNBC tumorigenesis through acting as molecular 'sponge' for miR-199a. |
| Pubmed ID | 28961506 |
| Year | 2017 |
| Title | Long non-coding RNA ANRIL promotes carcinogenesis via sponging miR-199a in triple-negative breast cancer. |
| External Links |
| Links for ANRIL | GenBank HGNC lncrnadb Noncode |
| Links for triple negative breast cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.